Photo and article don’t matter/Photo = Getty Images
Interest is increasing as to who will take the place of the new coronavirus infection (Corona 19)’domestic No. 2’treatment.
According to the Ministry of Food and Drug Safety on the 18th, the approved COVID-19 treatments in Korea are Gilead Science Korea’s Becluriju (ingredient name remdesivir) and Celltrion’s Rekironaju (ingredient name regdanvimab). Among them, Rekkirona is the’domestic No. 1’Corona 19 treatment developed in Korea.
Chong Kun Dang and GC Green Cross Daewoong Pharmaceutical were mentioned as the leading candidates to occupy the position of the second domestic treatment. Chong Kun Dang applied for an item license from the Ministry of Food and Drug Safety on the 8th of this month, leading the way, but missed the position of’No. 2’as the treatment effect was not recognized at the verification advisory group meeting of the Ministry of Food and Drug Safety the day before.
Although Chong Kun Dang’s permission has been canceled, GC Green Cross is working on the final work to apply for a corona 19 blood system treatment. As of December 31 of last year, GC Green Cross has analyzed and summarized related data after completing the administration of the corona 19 blood system drug’GC5131A’ for the subjects of the phase 2 clinical trial.
Daewoong Pharmaceutical is also conducting phase 2 and 3 clinical trials to develop Hoy Star tablet (ingredient name camostat mesylate) as a treatment for COVID-19. The specific permit application plan was not disclosed. Daewoong Pharmaceutical is also conducting phase 3 in parallel to confirm the effects of Hoystar tablets on the prevention of Corona 19.
In addition, among domestic pharmaceutical companies, Bukwang Pharmaceutical, Shinpoong Pharmaceutical, Crystal Genomics, Donghwa Pharmaceutical, Immunmed Green Cross Wellbeing, etc. are conducting phase 2 clinical trials for the development of COVID-19 treatment.
Reporter Lee Song-ryul [email protected]
Ⓒ Hankyung.com prohibits unauthorized reproduction and redistribution